AKAO 2018 Proxy Statement

9 The following table sets forth, for the Class I directors who are standing for election and for our other current directors who will continue in office after the Annual Meeting, information with respect to their position/office held with the Company and their ages as of March 31, 2018: Name Age Position/Office Held With the Company Director Since Class I Directors whose terms expire at the 2018 Annual Meeting of Stockholders and who are standing for election at the Annual Meeting Karen Bernstein, Ph.D. (1)(3) 65 Director 2017 Michael Fischbach, Ph.D. (3) 37 Director 2015 John W. Smither (1)(2) 65 Director 2013 Class II Directors whose terms expire at the 2019 Annual Meeting of Stockholders Halley Gilbert (1) 48 Director 2017 Kenneth J. Hillan, M.B., Ch.B. 57 President, R&D, President of Achaogen and Director 2011 Gregory Stea (2) 60 Director 2015 Class III Directors whose terms expire at the 2020 Annual Meeting of Stockholders John C. Doyle (2) 49 Director 2012 Kent E. Lieginger, Pharm.D. (3) 66 Director 2015 Bryan E. Roberts, Ph.D. 51 Chairman of the Board 2004 Blake Wise 47 Chief Executive Officer and Director 2018 (1) Member of the Audit Committee. (2) Member of the Compensation Committee. (3) Member of the Nominating and Corporate Governance Committee. Set forth below is biographical information for the nominees and each person whose term of office as a director will continue after the Annual Meeting. The following includes certain information regarding our directors’ individual experience, qualifications, attributes and skills that led the board of directors to conclude that they should serve as directors. Nominees for Election to a Three-Year Term Expiring at the 2021 Annual Meeting of Stockholders Karen Bernstein, Ph.D . Dr. Bernstein has served on Achaogen’s board of directors since July 2017. Dr. Bernstein is currently the Chairman of BioCentury. From 1992 to September 2015, Dr. Bernstein was the Chairman and Editor-in-Chief of BioCentury where she wrote and published on biotechnology developments. Dr. Bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of The WorldVIEW 100 most influential people in biotech today by Scientific American (2015) and receiving a Special Recognition award at the American Liver Foundation’s Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation (2007). Dr. Bernstein served for many years as a member of the Brandeis University Science Advisory Council. She is on the board of trustees of the Keck Graduate Institute (“KGI”) of the Applied Life Sciences and is a member of the board of advisors of KGI’s School of Pharmacy. Dr. Bernstein is also a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain. From September 2015 to October 2016, she served on the board of directors of Vitae Pharmaceuticals Inc., which was acquired by Allergan plc. Dr. Bernstein holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University. Dr. Bernstein brings to our board of directors significant knowledge and experience in biotechnology. Michael Fischbach , Ph.D. Dr. Fischbach has served on Achaogen’s board of directors since November 2015. Since September 2017, Dr. Fischbach has served as an Associate Professor at Stanford University in the Department of Bioengineering and as a member of Stanford ChEM-H, an interdisciplinary institute that uses chemistry, engineering, and medicine to improve human health. Dr. Fischbach’s laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Prior to Stanford from September 2009 to September 2017, he was an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF, and prior to that he spent two years as an independent fellow at Massachusetts General Hospital. Dr. Fischbach is a recipient of the NIH Director's Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, and a